|
Phase I Study of Intraperitoneal PV701 in Patients With Advanced or Recurrent Malignancy Largely Confined to the Peritoneal Cavity
Background: PV701 may be able to kill tumor cells while leaving normal cells undamaged. This is a Phase I trial to study the effectiveness of PV701 in treating patients who have advanced or recurrent ovarian epithelial, fallopian tube, primary peritoneal, colorectal, or other cancer within the peritoneal cavity. Memorial Sloan-Kettering Cancer Center Owen A. O'Connor, MD, PhD, Protocol Chair Ph: 212-639-8889 Location/Contacts: New York New York Memorial Sloan-Kettering Cancer Center Leonard Bruce Saltz, MD Ph: 212-639-2501 Owen A. O'Connor, MD, PhD Ph: 212-639-8889
|
 |
|